Comment on

• Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.

  Yu C, Dasmahapatra G, Dent P, Grant S. Yu C, et al. Leukemia. 2005 Sep;19(9):1579-89. doi: 10.1038/sj.leu.2403868. Leukemia. 2005. Retraction in: Leukemia. 2016 Jun;30(6):1452. doi: 10.1038/leu.2016.7. PMID: 16015388 Retracted.
• The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism.

  Dasmahapatra G, Rahmani M, Dent P, Grant S. Dasmahapatra G, et al. Blood. 2006 Jan 1;107(1):232-40. doi: 10.1182/blood-2005-06-2302. Epub 2005 Sep 15. Blood. 2006. Retraction in: Blood. 2019 Jul 4;134(1):95. doi: 10.1182/blood-2019-05-901215. PMID: 16166589 Free PMC article. Retracted.
• Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.

  Dasmahapatra G, Almenara JA, Grant S. Dasmahapatra G, et al. Mol Pharmacol. 2006 Jan;69(1):288-98. doi: 10.1124/mol.105.016154. Epub 2005 Oct 11. Mol Pharmacol. 2006. Retraction in: Mol Pharmacol. 2019 Apr;95(4):335. doi: 10.1124/mol.105.016154retraction. PMID: 16219908 Retracted.
• Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.

  Dasmahapatra G, Nguyen TK, Dent P, Grant S. Dasmahapatra G, et al. Leuk Res. 2006 Oct;30(10):1263-72. doi: 10.1016/j.leukres.2006.01.005. Epub 2006 Feb 14. Leuk Res. 2006. PMID: 16481037
• Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.

  Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S. Dasmahapatra G, et al. Clin Cancer Res. 2007 Jul 15;13(14):4280-90. doi: 10.1158/1078-0432.CCR-07-0835. Clin Cancer Res. 2007. Retraction in: Clin Cancer Res. 2016 Oct 1;22(19):4959. doi: 10.1158/1078-0432.CCR-16-1914. PMID: 17634558 Retracted.
• Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.

  Dasmahapatra G, Lembersky D, Rahmani M, Kramer L, Friedberg J, Fisher RI, Dent P, Grant S. Dasmahapatra G, et al. Cancer Biol Ther. 2009 May;8(9):808-19. doi: 10.4161/cbt.8.9.8131. Epub 2009 May 8. Cancer Biol Ther. 2009. PMID: 19270531 Free PMC article.
• The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.

  Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S. Dasmahapatra G, et al. Blood. 2010 Jun 3;115(22):4478-87. doi: 10.1182/blood-2009-12-257261. Epub 2010 Mar 16. Blood. 2010. Retraction in: Blood. 2019 Jul 4;134(1):95. doi: 10.1182/blood-2019-05-901223. PMID: 20233973 Free PMC article. Retracted.
• Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.

  Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S. Dasmahapatra G, et al. Mol Cancer Ther. 2011 Sep;10(9):1686-97. doi: 10.1158/1535-7163.MCT-10-1108. Epub 2011 Jul 12. Mol Cancer Ther. 2011. Retraction in: Mol Cancer Ther. 2019 Jun;18(6):1179. doi: 10.1158/1535-7163.MCT-19-0469. PMID: 21750224 Free PMC article. Retracted.
• Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.

  Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S. Dasmahapatra G, et al. Mol Cancer Ther. 2012 May;11(5):1122-32. doi: 10.1158/1535-7163.MCT-12-0021. Epub 2012 Mar 12. Mol Cancer Ther. 2012. Retraction in: Mol Cancer Ther. 2019 Jun;18(6):1180. doi: 10.1158/1535-7163.MCT-19-0470. PMID: 22411899 Free PMC article. Retracted.
• The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.

  Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S. Dasmahapatra G, et al. Br J Haematol. 2013 Apr;161(1):43-56. doi: 10.1111/bjh.12206. Epub 2013 Jan 30. Br J Haematol. 2013. PMID: 23360303 Free PMC article.
• In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.

  Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S. Dasmahapatra G, et al. Mol Cancer Ther. 2014 Dec;13(12):2886-97. doi: 10.1158/1535-7163.MCT-14-0220. Epub 2014 Sep 19. Mol Cancer Ther. 2014. Retraction in: Mol Cancer Ther. 2019 Jun;18(6):1181. doi: 10.1158/1535-7163.MCT-19-0471. PMID: 25239935 Free PMC article. Retracted.